Obstructive Sleep ApneaPhase 2NCT06960200
Phototherapy for Non-responders to Oral Appliance Therapy for Obstructive Sleep Apnea
A Phase 2 study testing Phototherapy in people with Obstructive Sleep Apnea, run by University of Alberta at 1 site in Canada.
Trial summary
Obstructive sleep apnea (OSA) is a medical condition where a person has great difficulty with breathing, or stops breathing all together, while asleep. This is a medical condition for which one of the current standard treatments is the use of a custom made dental appliance to help hold the person's airway open while… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- Phototherapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 528 participants
- Where
- 1 siteCanada
- Study dates
- 5 Jan 2024to Dec 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- diagnosed with OSA
- incomplete treatment with OAT/MAD
Who cannot join
- not diagnosed with OSA
- using CPAP
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Alberta, Edmonton, Alberta T6G 2E1
Edmonton
Enoch Ng, 780-407-5550, enoch@ualberta.ca
About this study
Obstructive sleep apnea (OSA) is a medical condition where a person has great difficulty with breathing, or stops breathing all together, while asleep. This is a medical condition for which one of the current standard treatments is the use of a custom made dental appliance to help hold the person's airway open while asleep so that the person does not suffocate while sleeping. However, while the majority of OSA patients are able to tolerate the use of oral appliance therapy (OAT) for OSA, some patients are incomplete responders to OAT. These patients, despite having improvement, may still have a disease index above the diagnostic threshold for OSA.
Phototherapy (laser therapy) has been used as a method to stiffen the soft palate and parts of the tongue to prevent their collapse. This is a type of cold laser therapy that does not cut/ablate tissue (similar to healing laser therapies). This has been shown to help with both snoring and can also help with OSA, as soft palate and tongue collapse are common areas for where OSA occurs inside the airway. A recent pilot study has shown that phototherapy on its own may be able to treat selected patients with mild, moderate, or severe OSA. To our knowledge, there are no contraindications to combining phototherapy and dental sleep appliance therapy.
Read the detailed description
The purpose of this study is to determine whether phototherapy (nightlase/quiet night laser protocol) can change oral appliance therapy (OAT) incomplete responders into complete responders for the treatment of obstructive sleep apnea (OSA). Patients who are incomplete responders to OAT will become complete responders (as defined as a reduction of 50% and below 10) with the adjunctive use of phototherapy for OSA. Per the American Academy of Sleep Medicine, first line treatment for OSA is CPAP. Patients who are unable to tolerate CPAP or otherwise decline CPAP may be treated through OAT. However, which compliance with OAT is significantly greater than CPAP, overall efficacy of OAT is not as high as CPAP. Further treatment options for patients with are incomplete responders to OAT are limited (other options include surgical interventions such as bariatric surgery and/or jaw surgery). The use of phototherapy for OAT incomplete responders offers the possibility of changing the response pattern for these patients into complete response which may provide more complete treatment rather than partial management for their OSA. Data to be collected for this study will be standard data collected for dental sleep appliance therapy. This includes mandibular position (in digital impression form and as OJ and OB recordings), range of motion, side effects/adverse reactions, titrations (% and number), total time required for treatment, medical history, CBCT imaging, biographical data, phototherapy exposure settings, etc.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- Phototherapy
- Medical subject headings
- Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PhototherapyDevice
Non-surgical laser therapy (phototherapy)
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Not described |
| NL C3 | Experimental | Not described Receives: Device: Phototherapy |
| QN | Experimental | Not described Receives: Device: Phototherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
OSA disease index
Measured: 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2025
- Study start5 Jan 2024
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 528 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06960200
- Sponsor's protocol ID
- Pro00125341
- Status last verified
- May 2026
- First submitted
- 28 Apr 2025
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phototherapy for Non-responders to Oral Appliance Therapy for Obstructive Sleep Apnea
- ClinicalTrials.gov ID
- NCT06960200
- Acronym / sponsor ID
- Pro00125341
- Conditions
- Obstructive Sleep Apnea
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 528 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 5 Jan 2024 (actual)
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 7 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obstructive sleep apnea (OSA) is a medical condition where a person has great difficulty with breathing, or stops breathing all together, while asleep. This is a medical condition for which one of the current standard treatments is the use of a custom made dental appliance to help hold the person's airway open while asleep so that the person does not suffocate while sleeping. However, while the majority of OSA patients are able to tolerate the use of oral appliance therapy (OAT) for OSA, some patients are incomplete responders to OAT. These patients, despite having improvement, may still have a disease index above the diagnostic threshold for OSA.
Phototherapy (laser therapy) has been used as a method to stiffen the soft palate and parts of the tongue to prevent their collapse. This is a type of cold laser therapy that does not cut/ablate tissue (similar to healing laser therapies). This has been shown to help with both snoring and can also help with OSA, as soft palate and tongue collapse are common areas for where OSA occurs inside the airway. A recent pilot study has shown that phototherapy on its own may be able to treat selected patients with mild, moderate, or severe OSA. To our knowledge, there are no contraindications to combining phototherapy and dental sleep appliance therapy.
Detailed description
The purpose of this study is to determine whether phototherapy (nightlase/quiet night laser protocol) can change oral appliance therapy (OAT) incomplete responders into complete responders for the treatment of obstructive sleep apnea (OSA). Patients who are incomplete responders to OAT will become complete responders (as defined as a reduction of 50% and below 10) with the adjunctive use of phototherapy for OSA. Per the American Academy of Sleep Medicine, first line treatment for OSA is CPAP. Patients who are unable to tolerate CPAP or otherwise decline CPAP may be treated through OAT. However, which compliance with OAT is significantly greater than CPAP, overall efficacy of OAT is not as high as CPAP. Further treatment options for patients with are incomplete responders to OAT are limited (other options include surgical interventions such as bariatric surgery and/or jaw surgery). The use of phototherapy for OAT incomplete responders offers the possibility of changing the response pattern for these patients into complete response which may provide more complete treatment rather than partial management for their OSA. Data to be collected for this study will be standard data collected for dental sleep appliance therapy. This includes mandibular position (in digital impression form and as OJ and OB recordings), range of motion, side effects/adverse reactions, titrations (% and number), total time required for treatment, medical history, CBCT imaging, biographical data, phototherapy exposure settings, etc.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | – |
| NL C3 | Experimental | Device: Phototherapy |
| QN | Experimental | Device: Phototherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- diagnosed with OSA
- incomplete treatment with OAT/MAD
Key exclusion criteria (2 listed)
- not diagnosed with OSA
- using CPAP
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PhototherapyNon-surgical laser therapy (phototherapy) | Device | NL C3, QN |
Primary outcome
OSA disease index
Time frame: 4 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Phototherapy in people with Obstructive Sleep Apnea, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Enoch Ng (780-407-5550, enoch@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OSA disease index (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.